Does the media refer more to ANVS or ANIK?

In the previous week, Anika Therapeutics had 1 more articles in the media than Annovis Bio. MarketBeat recorded 2 mentions for Anika Therapeutics and 1 mentions for Annovis Bio. Anika Therapeutics' average media sentiment score of 0.49 beat Annovis Bio's score of 0.00 indicating that Anika Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Annovis Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Anika Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to CERS or ANIK?

In the previous week, Cerus had 2 more articles in the media than Anika Therapeutics. MarketBeat recorded 4 mentions for Cerus and 2 mentions for Anika Therapeutics. Cerus' average media sentiment score of 0.76 beat Anika Therapeutics' score of 0.49 indicating that Cerus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cerus 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Anika Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer ANIK or OSUR?

In the previous week, Anika Therapeutics had 1 more articles in the media than OraSure Technologies. MarketBeat recorded 2 mentions for Anika Therapeutics and 1 mentions for OraSure Technologies. OraSure Technologies' average media sentiment score of 1.11 beat Anika Therapeutics' score of 0.49 indicating that OraSure Technologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Anika Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral OraSure Technologies 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend ANIK or UTMD?

Anika Therapeutics presently has a consensus price target of $17.00, suggesting a potential upside of 12.88%. Given Anika Therapeutics' higher possible upside, analysts plainly believe Anika Therapeutics is more favorable than Utah Medical Products. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Anika Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Utah Medical Products 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Does the media refer more to ANIK or WST?

In the previous week, West Pharmaceutical Services had 6 more articles in the media than Anika Therapeutics. MarketBeat recorded 8 mentions for West Pharmaceutical Services and 2 mentions for Anika Therapeutics. West Pharmaceutical Services' average media sentiment score of 0.96 beat Anika Therapeutics' score of 0.49 indicating that West Pharmaceutical Services is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Anika Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral West Pharmaceutical Services 5 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Anika Therapeutics (ANIK) Competitors

$15.06 -0.19 (-1.25%)

Closing price 07/20/2026 04:00 PM Eastern

Extended Trading

$15.07 +0.01 (+0.07%)

As of 07/20/2026 05:01 PM Eastern

Compare

ANIK vs. ANVS, CERS, OSUR, UTMD, and WST

Should you buy Anika Therapeutics stock or one of its competitors? MarketBeat compares Anika Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Anika Therapeutics include Annovis Bio (ANVS), Cerus (CERS), OraSure Technologies (OSUR), Utah Medical Products (UTMD), and West Pharmaceutical Services (WST). These companies are all part of the "medical" sector.

How does Anika Therapeutics compare to Annovis Bio?

Annovis Bio (NYSE:ANVS) and Anika Therapeutics (NASDAQ:ANIK) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, profitability, earnings, institutional ownership, analyst recommendations, valuation, dividends and media sentiment.

Annovis Bio has a net margin of 0.00% compared to Anika Therapeutics' net margin of -9.52%. Anika Therapeutics' return on equity of -5.90% beat Annovis Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Annovis Bio	N/A	-318.08%	-215.47%
Anika Therapeutics	-9.52%	-5.90%	-4.52%

Anika Therapeutics has higher revenue and earnings than Annovis Bio. Anika Therapeutics is trading at a lower price-to-earnings ratio than Annovis Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Annovis Bio	N/A	N/A	-$28.85M	-$1.71	N/A
Anika Therapeutics	$112.82M	1.78	-$10.88M	-$0.79	N/A

15.8% of Annovis Bio shares are owned by institutional investors. Comparatively, 91.5% of Anika Therapeutics shares are owned by institutional investors. 20.8% of Annovis Bio shares are owned by company insiders. Comparatively, 12.1% of Anika Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Annovis Bio has a beta of 1.19, suggesting that its stock price is 19% more volatile than the broader market. Comparatively, Anika Therapeutics has a beta of 0.23, suggesting that its stock price is 77% less volatile than the broader market.

Annovis Bio presently has a consensus price target of $11.67, indicating a potential upside of 588.30%. Anika Therapeutics has a consensus price target of $17.00, indicating a potential upside of 12.88%. Given Annovis Bio's stronger consensus rating and higher probable upside, analysts plainly believe Annovis Bio is more favorable than Anika Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Annovis Bio	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
Anika Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Anika Therapeutics had 1 more articles in the media than Annovis Bio. MarketBeat recorded 2 mentions for Anika Therapeutics and 1 mentions for Annovis Bio. Anika Therapeutics' average media sentiment score of 0.49 beat Annovis Bio's score of 0.00 indicating that Anika Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Annovis Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Anika Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Annovis Bio and Anika Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Anika Therapeutics compare to Cerus?

Cerus (NASDAQ:CERS) and Anika Therapeutics (NASDAQ:ANIK) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, valuation, analyst recommendations, risk, institutional ownership, profitability and earnings.

In the previous week, Cerus had 2 more articles in the media than Anika Therapeutics. MarketBeat recorded 4 mentions for Cerus and 2 mentions for Anika Therapeutics. Cerus' average media sentiment score of 0.76 beat Anika Therapeutics' score of 0.49 indicating that Cerus is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cerus	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Anika Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Cerus has a beta of 1.77, meaning that its stock price is 77% more volatile than the broader market. Comparatively, Anika Therapeutics has a beta of 0.23, meaning that its stock price is 77% less volatile than the broader market.

Cerus has a net margin of -4.41% compared to Anika Therapeutics' net margin of -9.52%. Anika Therapeutics' return on equity of -5.90% beat Cerus' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cerus	-4.41%	-15.18%	-4.38%
Anika Therapeutics	-9.52%	-5.90%	-4.52%

Cerus presently has a consensus target price of $4.00, indicating a potential upside of 26.98%. Anika Therapeutics has a consensus target price of $17.00, indicating a potential upside of 12.88%. Given Cerus' stronger consensus rating and higher probable upside, equities analysts plainly believe Cerus is more favorable than Anika Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cerus	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Anika Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

78.4% of Cerus shares are owned by institutional investors. Comparatively, 91.5% of Anika Therapeutics shares are owned by institutional investors. 5.3% of Cerus shares are owned by insiders. Comparatively, 12.1% of Anika Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Anika Therapeutics has lower revenue, but higher earnings than Cerus. Cerus is trading at a lower price-to-earnings ratio than Anika Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cerus	$206.13M	3.06	-$15.63M	-$0.05	N/A
Anika Therapeutics	$112.82M	1.78	-$10.88M	-$0.79	N/A

Summary

Cerus beats Anika Therapeutics on 11 of the 16 factors compared between the two stocks.

How does Anika Therapeutics compare to OraSure Technologies?

Anika Therapeutics (NASDAQ:ANIK) and OraSure Technologies (NASDAQ:OSUR) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, valuation, risk, media sentiment, dividends, profitability and analyst recommendations.

91.5% of Anika Therapeutics shares are held by institutional investors. Comparatively, 93.5% of OraSure Technologies shares are held by institutional investors. 12.1% of Anika Therapeutics shares are held by company insiders. Comparatively, 4.7% of OraSure Technologies shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Anika Therapeutics has higher earnings, but lower revenue than OraSure Technologies. Anika Therapeutics is trading at a lower price-to-earnings ratio than OraSure Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anika Therapeutics	$112.82M	1.78	-$10.88M	-$0.79	N/A
OraSure Technologies	$115.02M	2.30	-$68.73M	-$1.04	N/A

Anika Therapeutics has a net margin of -9.52% compared to OraSure Technologies' net margin of -66.42%. Anika Therapeutics' return on equity of -5.90% beat OraSure Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anika Therapeutics	-9.52%	-5.90%	-4.52%
OraSure Technologies	-66.42%	-18.57%	-15.71%

Anika Therapeutics has a beta of 0.23, meaning that its stock price is 77% less volatile than the broader market. Comparatively, OraSure Technologies has a beta of 1.01, meaning that its stock price is 1% more volatile than the broader market.

In the previous week, Anika Therapeutics had 1 more articles in the media than OraSure Technologies. MarketBeat recorded 2 mentions for Anika Therapeutics and 1 mentions for OraSure Technologies. OraSure Technologies' average media sentiment score of 1.11 beat Anika Therapeutics' score of 0.49 indicating that OraSure Technologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Anika Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
OraSure Technologies	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Anika Therapeutics currently has a consensus target price of $17.00, suggesting a potential upside of 12.88%. OraSure Technologies has a consensus target price of $3.00, suggesting a potential downside of 22.08%. Given Anika Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Anika Therapeutics is more favorable than OraSure Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anika Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
OraSure Technologies	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Summary

Anika Therapeutics beats OraSure Technologies on 10 of the 16 factors compared between the two stocks.

How does Anika Therapeutics compare to Utah Medical Products?

Anika Therapeutics (NASDAQ:ANIK) and Utah Medical Products (NASDAQ:UTMD) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, institutional ownership, profitability, earnings, media sentiment, dividends, risk and analyst recommendations.

In the previous week, Anika Therapeutics had 2 more articles in the media than Utah Medical Products. MarketBeat recorded 2 mentions for Anika Therapeutics and 0 mentions for Utah Medical Products. Anika Therapeutics' average media sentiment score of 0.49 beat Utah Medical Products' score of 0.00 indicating that Anika Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Anika Therapeutics	Neutral
Utah Medical Products	Neutral

Anika Therapeutics has a beta of 0.23, indicating that its share price is 77% less volatile than the broader market. Comparatively, Utah Medical Products has a beta of 0.36, indicating that its share price is 64% less volatile than the broader market.

Anika Therapeutics presently has a consensus price target of $17.00, suggesting a potential upside of 12.88%. Given Anika Therapeutics' higher possible upside, analysts plainly believe Anika Therapeutics is more favorable than Utah Medical Products.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anika Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Utah Medical Products	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Utah Medical Products has lower revenue, but higher earnings than Anika Therapeutics. Anika Therapeutics is trading at a lower price-to-earnings ratio than Utah Medical Products, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anika Therapeutics	$112.82M	1.78	-$10.88M	-$0.79	N/A
Utah Medical Products	$38.52M	5.72	$11.29M	$3.38	20.50

Utah Medical Products has a net margin of 28.90% compared to Anika Therapeutics' net margin of -9.52%. Utah Medical Products' return on equity of 9.13% beat Anika Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anika Therapeutics	-9.52%	-5.90%	-4.52%
Utah Medical Products	28.90%	9.13%	8.86%

91.5% of Anika Therapeutics shares are held by institutional investors. Comparatively, 69.6% of Utah Medical Products shares are held by institutional investors. 12.1% of Anika Therapeutics shares are held by company insiders. Comparatively, 8.0% of Utah Medical Products shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Utah Medical Products beats Anika Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Anika Therapeutics compare to West Pharmaceutical Services?

Anika Therapeutics (NASDAQ:ANIK) and West Pharmaceutical Services (NYSE:WST) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, media sentiment, profitability, dividends, analyst recommendations and valuation.

West Pharmaceutical Services has a net margin of 16.85% compared to Anika Therapeutics' net margin of -9.52%. West Pharmaceutical Services' return on equity of 19.03% beat Anika Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anika Therapeutics	-9.52%	-5.90%	-4.52%
West Pharmaceutical Services	16.85%	19.03%	14.06%

Anika Therapeutics currently has a consensus target price of $17.00, suggesting a potential upside of 12.88%. West Pharmaceutical Services has a consensus target price of $363.17, suggesting a potential upside of 2.85%. Given Anika Therapeutics' higher probable upside, equities research analysts clearly believe Anika Therapeutics is more favorable than West Pharmaceutical Services.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anika Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
West Pharmaceutical Services	0 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	3.00

Anika Therapeutics has a beta of 0.23, meaning that its stock price is 77% less volatile than the broader market. Comparatively, West Pharmaceutical Services has a beta of 1.16, meaning that its stock price is 16% more volatile than the broader market.

In the previous week, West Pharmaceutical Services had 6 more articles in the media than Anika Therapeutics. MarketBeat recorded 8 mentions for West Pharmaceutical Services and 2 mentions for Anika Therapeutics. West Pharmaceutical Services' average media sentiment score of 0.96 beat Anika Therapeutics' score of 0.49 indicating that West Pharmaceutical Services is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Anika Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
West Pharmaceutical Services	5 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

91.5% of Anika Therapeutics shares are owned by institutional investors. Comparatively, 93.9% of West Pharmaceutical Services shares are owned by institutional investors. 12.1% of Anika Therapeutics shares are owned by insiders. Comparatively, 0.6% of West Pharmaceutical Services shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

West Pharmaceutical Services has higher revenue and earnings than Anika Therapeutics. Anika Therapeutics is trading at a lower price-to-earnings ratio than West Pharmaceutical Services, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anika Therapeutics	$112.82M	1.78	-$10.88M	-$0.79	N/A
West Pharmaceutical Services	$3.07B	8.11	$493.70M	$7.48	47.21

Summary

West Pharmaceutical Services beats Anika Therapeutics on 15 of the 17 factors compared between the two stocks.

Get Anika Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ANIK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ANIK vs. The Competition

Export

Metric	Anika Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$202.91M	$3.69B	$6.89B	$12.28B
Dividend Yield	N/A	2.16%	2.67%	9.39%
P/E Ratio	-19.06	20.49	27.10	23.94
Price / Sales	1.78	300.39	517.51	91.94
Price / Cash	N/A	60.31	26.68	47.25
Price / Book	1.51	7.92	10.66	6.14
Net Income	-$10.88M	$23.81M	$3.60B	$331.74M
7 Day Performance	-2.96%	-1.09%	-1.23%	-1.81%
1 Month Performance	4.44%	2.56%	1.11%	-1.44%
1 Year Performance	40.88%	42.16%	23.65%	16.33%

Anika Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ANIK Anika Therapeutics	2.3217 of 5 stars	$15.06 -1.2%	$17.00 +12.9%	+43.4%	$202.91M	$112.82M	N/A	300	Positive News
ANVS Annovis Bio	2.4642 of 5 stars	$1.75 -6.2%	$11.67 +568.6%	-36.2%	$64.44M	N/A	N/A	3
CERS Cerus	3.2017 of 5 stars	$3.09 -1.0%	$4.00 +29.4%	+131.6%	$625.15M	$206.13M	N/A	290	Short Interest Decrease
OSUR OraSure Technologies	1.5939 of 5 stars	$4.30 flat	$3.00 -30.2%	+20.3%	$295.70M	$115.02M	N/A	840	Positive News
UTMD Utah Medical Products	0.9249 of 5 stars	$70.01 +3.0%	N/A	+24.8%	$216.39M	$38.52M	20.71	180	Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ANIK) was last updated on 7/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Anika Therapeutics (ANIK) Competitors

ANIK vs. ANVS, CERS, OSUR, UTMD, and WST

How does Anika Therapeutics compare to Annovis Bio?

Summary

How does Anika Therapeutics compare to Cerus?

Summary

How does Anika Therapeutics compare to OraSure Technologies?

Summary

How does Anika Therapeutics compare to Utah Medical Products?

Summary

How does Anika Therapeutics compare to West Pharmaceutical Services?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANIK vs. The Competition

Anika Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Anika Therapeutics (ANIK) Competitors

ANIK vs. ANVS, CERS, OSUR, UTMD, and WST

How does Anika Therapeutics compare to Annovis Bio?

Is ANVS or ANIK more profitable?

Which has better earnings and valuation, ANVS or ANIK?

Do insiders & institutionals believe in ANVS or ANIK?

Which has more volatility & risk, ANVS or ANIK?

Do analysts rate ANVS or ANIK?

Does the media refer more to ANVS or ANIK?

Summary

How does Anika Therapeutics compare to Cerus?

Does the media refer more to CERS or ANIK?

Which has more volatility and risk, CERS or ANIK?

Is CERS or ANIK more profitable?

Do analysts prefer CERS or ANIK?

Do institutionals and insiders believe in CERS or ANIK?

Which has preferable valuation and earnings, CERS or ANIK?

Summary

How does Anika Therapeutics compare to OraSure Technologies?

Do insiders and institutionals have more ownership in ANIK or OSUR?

Which has preferable valuation & earnings, ANIK or OSUR?

Is ANIK or OSUR more profitable?

Which has more risk & volatility, ANIK or OSUR?

Does the media prefer ANIK or OSUR?

Do analysts prefer ANIK or OSUR?

Summary

How does Anika Therapeutics compare to Utah Medical Products?

Does the media refer more to ANIK or UTMD?

Which has more volatility and risk, ANIK or UTMD?

Do analysts recommend ANIK or UTMD?

Which has preferable earnings & valuation, ANIK or UTMD?

Is ANIK or UTMD more profitable?

Do insiders & institutionals have more ownership in ANIK or UTMD?

Summary

How does Anika Therapeutics compare to West Pharmaceutical Services?

Is ANIK or WST more profitable?

Do analysts rate ANIK or WST?

Which has more volatility and risk, ANIK or WST?

Does the media refer more to ANIK or WST?

Do insiders and institutionals have more ownership in ANIK or WST?

Which has preferable earnings and valuation, ANIK or WST?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANIK vs. The Competition

Anika Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools